New eczema drug shows promise in Mid-Stage trial

NCT ID NCT07599813

Disease control Sponsor: Apollo Therapeutics Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a safer and more effective treatment option for people whose eczema is not well controlled with current therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-65 inclusive, at the time of signing the informed consent. 2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria. 3. Participants with moderate-to-severe AD defined by: 1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline. 2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline. 3. EASI score of ≥ 16 at Screening and at Baseline. 4. Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed. 4. Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks. 5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 6. Participant provides signed informed consent Exclusion Criteria: 1. History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study. 2. Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline. 3. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement. 4. Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator. 5. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement. 6. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes. 7. Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator. 8. Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit. 9. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test. 10. Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+). 11. Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled. 12. Evidence of active or latent tuberculosis. 13. Receipt of live or attenuated live vaccine within 6 weeks prior to screening. 14. Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study. 15. Participant is known to have immune deficiency or is immunocompromised 16. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of: * Completely resected basal cell or squamous cell carcinoma of the skin. * Carcinoma in situ of the cervix. 17. Has had previous exposure to anti-IL-18 therapy. 18. Known allergy/sensitivity to any component of IMP. 19. History of use of any of these medications as follows: 1. Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline. 2. Systemic JAKi within 4 weeks prior to Baseline. 3. Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths. 4. Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral/injectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed. 5. Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening. 6. Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening. 7. UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study. 8. PUVA treatment within 4 weeks prior to Baseline 9. Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline 10. Topical products containing urea within 1 week prior to Baseline 11. Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline 12. Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline. 20. Female participant who is pregnant or breastfeeding or trying to conceive. 21. Participant considered unlikely to adhere to treatment and/or follow the protocol in the opinion of the Investigator.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema atopic IgE-mediated allergic disorder dermatitis Eczema skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC Atopic dermatitis Dermatitis Dermatitis, atopic Dermatologic disease Eczema Eczema atopic dermatitis Eczema, atopic

How to take part

Only the study team decides who joins. These are the ways to reach them.

The study's own enquiry address

This study publishes an address for enquiries. See it below .
The places running it

85 sites in 8 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Show contact details

Locations

ABMED Clinical Research Corp.
RECRUITING

Cape Coral, Florida, 33904, United States
Ada West Research, LLC
RECRUITING

Meridian, Idaho, 83646, United States

Contact Email: •••••@•••••
AllerVie Clinical Research
RECRUITING

Birmingham, Alabama, 35209, United States

Contact Email: •••••@•••••
Beacon Dermatology
NOT_YET_RECRUITING

Calgary, Alberta, Canada
Best Skin Research, LLC
RECRUITING

Camp Hill, Pennsylvania, 17011, United States
CCR Ostrava s.r.o.
NOT_YET_RECRUITING

Ostrava, Czechia
CM Pratia Katowice
NOT_YET_RECRUITING

Katowice, Poland
Cahaba Dermatology and Skin Health Center
RECRUITING

Birmingham, Alabama, 35244, United States
Centre de Recherche Saint-Louis (Sherbrooke)
RECRUITING

Sherbrooke, Quebec, Canada
Chesapeake Clinical Research, Inc
RECRUITING

Pasadena, Maryland, 21122, United States
ClinOhio Research Services
RECRUITING

Columbus, Ohio, 43213, United States
Clinical Best Solution Sp. z o.o.
NOT_YET_RECRUITING

Lublin, Poland
Clintrial s.r.o.
NOT_YET_RECRUITING

Prague, Czechia
Complejo Hospitalario Universitario de Santiago de Compostela
NOT_YET_RECRUITING

Santiago de Compostela, Spain
DS Research of Southern Indiana,LLC
RECRUITING

Clarksville, Indiana, 47129, United States
Dawes Fretzin Clinical Research Group, LLC
RECRUITING

Indianapolis, Indiana, 46250, United States
Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center)
NOT_YET_RECRUITING

Debrecen, Hungary
Dept. Dermatology, Venereology and Dermatooncology, Semmelweis University
NOT_YET_RECRUITING

Budapest, Hungary
DermEdge Research
RECRUITING

Mississauga, Ontario, Canada
Dermatologikum Hamburg GmbH
NOT_YET_RECRUITING

Hamburg, Germany
Dermatology Research Associates
RECRUITING

Los Angeles, California, 90048, United States
Dermatology Trial Associates, Inc
RECRUITING

Bryant, Arkansas, 72022, United States
Dermedea Clinic
NOT_YET_RECRUITING

Gdansk, Poland
Eminent Clinical Research and Associates
NOT_YET_RECRUITING

North Lauderdale, Florida, 33068, United States

Contact Email: •••••@•••••
Endeavor Health
NOT_YET_RECRUITING

Skokie, Illinois, 60077, United States
FACET Dermatology
NOT_YET_RECRUITING

Toronto, Ontario, Canada
FXM Clinical Research Miami, LLC
RECRUITING

Miami, Florida, 33155, United States

Contact Email: •••••@•••••
Fachklinik Bad Bentheim
NOT_YET_RECRUITING

Bad Bentheim, Germany
Fakultni Nemocnice Kralovske Vinohrady
NOT_YET_RECRUITING

Prague, Czechia
Georgia Skin & Cancer Center
NOT_YET_RECRUITING

Savannah, Georgia, 31406, United States
Hautarztpraxis Dr. Hoffmann
NOT_YET_RECRUITING

Witten, Germany
Hospital General Universitario Dr. Balmis
NOT_YET_RECRUITING

Alicante, Spain
Hospital Universitari Germans Trias i Pujol
NOT_YET_RECRUITING

Badalona, Spain
Hospital Universitario La Paz
NOT_YET_RECRUITING

La Paz, Spain
Hospital Universitario Miguel Servet
NOT_YET_RECRUITING

Zaragoza, Spain
Integrative Skin Science and Research
RECRUITING

Sacramento, California, 95815, United States

Contact Email: •••••@•••••
Klinika Ambroziak Dermatologia
NOT_YET_RECRUITING

Warsaw, Poland
Klinika Zdybski - Dermedic (Kielce)
NOT_YET_RECRUITING

Kielce, Poland
Komplex Labor Kft
NOT_YET_RECRUITING

Szeged, Hungary
Laser Clinic S.C. Andrzej Krolicki, Tomasz Kochanowski
NOT_YET_RECRUITING

Szczecin, Poland
Laser Rejuvenation Clinics Edmonton D.T. Inc.
NOT_YET_RECRUITING

Calgary, Alberta, Canada
Laser Rejuvenation Clinics Edmonton D.T. Inc.
RECRUITING

Edmonton, Alberta, Canada
Marvel Research, LLC
RECRUITING

Huntington Beach, California, 92648, United States
Medical Center Kazanlak EOOD
NOT_YET_RECRUITING

Kazanlak, Bulgaria
Medical Center Medconsult Burgas EOOD
NOT_YET_RECRUITING

Burgas, Bulgaria
Medical Center Medconsult Pleven OOD
NOT_YET_RECRUITING

Pleven, Bulgaria
Medical Center Medconsult Pleven-Lovech Branch
NOT_YET_RECRUITING

Lovech, Bulgaria
Medical Centre Pratia Clinic EOOD
NOT_YET_RECRUITING

Varna, Bulgaria
Medicus Clinic
NOT_YET_RECRUITING

Wroclaw, Poland
Metropolis Dermatology
RECRUITING

Los Angeles, California, 90025, United States
NMC Research LLC
NOT_YET_RECRUITING

Tampa, Florida, 33614, United States

Contact Email: •••••@•••••
NZOZ Centrum Medyczne KERmed
NOT_YET_RECRUITING

Bydgoszcz, Poland
NZOZ Hipokrates
NOT_YET_RECRUITING

Piotrkow Trybunalski, Poland
North York Research Inc.
RECRUITING

Toronto, Ontario, Canada
Northridge Clinical Trials
RECRUITING

Northridge, California, 91325, United States
OptiTrial
NOT_YET_RECRUITING

Chojnice, Poland
Paradigm Clinical Research Centers, LLC: Wheat Ridge
RECRUITING

Wheat Ridge, Colorado, 80033, United States
Pecsi Tudomanyegyetem
NOT_YET_RECRUITING

Pécs, Hungary
Praglandia s.r.o.
NOT_YET_RECRUITING

Prague, Czechia
Pratia Pardubice a.s.
NOT_YET_RECRUITING

Pardubice, Czechia
Pratia Prague
NOT_YET_RECRUITING

Prague, Czechia
Progressive Clinical Research, PA
RECRUITING

San Antonio, Texas, 78213, United States
Provita Sp. z o. o.
NOT_YET_RECRUITING

Katowice, Poland
Quality Care Clinical Research
RECRUITING

Miami, Florida, 33101, United States
Red River Research Partners, LLC
RECRUITING

Fargo, North Dakota, 58103, United States
Rejuvenation Dermatology Clinic Edmonton South
RECRUITING

Edmonton, Alberta, Canada
Sadick Research Group, LLC
RECRUITING

New York, New York, 10021, United States
Saguaro Dermatology Associates
RECRUITING

Phoenix, Arizona, 85018, United States

Contact Email: •••••@•••••
Saskatoon Dermatology Centre
RECRUITING

Saskatoon, Saskatchewan, Canada
Skin Cancer and Dermatology Institute
RECRUITING

Reno, Nevada, 89509, United States
Skin Care Research
RECRUITING

Hollywood, Florida, 33021, United States
Softskin Medical Center Dr Elzbieta Wojtowicz-Prus
NOT_YET_RECRUITING

Wroclaw, Poland
Trail Horizon
NOT_YET_RECRUITING

Clifton, New Jersey, 07013, United States
Trial Pharma Kft.
NOT_YET_RECRUITING

Békéscsaba, Hungary
Twoja Przychodnia Poznanskie Centrum Medyczne Sp.
NOT_YET_RECRUITING

Poznan, Poland
Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
NOT_YET_RECRUITING

Szczecin, Poland
UPMC Department of Dermatology
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Universitatsklinikum Frankfurt Klinik fur Dermatologie, Venerologie und Allergologie
NOT_YET_RECRUITING

Frankfurt, Germany
University Hospital Dresden
NOT_YET_RECRUITING

Dresden, Germany
University Hospital of Muenster
NOT_YET_RECRUITING

Münster, Germany
University of California Los Angeles
NOT_YET_RECRUITING

Los Angeles, California, 90095, United States
University of Luebeck
NOT_YET_RECRUITING

Lübeck, Germany
University of Szeged
NOT_YET_RECRUITING

Szeged, Hungary
Valiance Clinical Research - Tarzana
NOT_YET_RECRUITING

Tarzana, California, 91356, United States
Ziaderm Research LLC
RECRUITING

North Miami Beach, Florida, 33162, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.